Article

Around the Practice: January 2021 Virtual Tumor Board

Author(s):

Urology Times staff

Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.

Tune in for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma. As the complexity of cancer management continues to mount, clinicians frequently face difficult therapeutic decisions that mandate the input from colleagues and various specialties critical for optimizing patient care.

Hear experts provide their perspectives from urology, medical oncology, and radiation oncology on multiple cases:

  • Upper tract Urothelial Carcinoma
  • Incidentally discovered Renal mass and the role of biopsy and molecular testing

We will be polling the audience live to interact with the experts on how they would treat.

Register at: https://primetime.bluejeans.com/a2m/register/bcgrjfbp?utm_source=social&utm_medium=post&utm_campaign=registration

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer
Related Content
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO
"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC
October 3rd 2024

Phase 3 trial launches of UGN-103 in low-grade, intermediate-risk NMIBC

Hannah Clarke
In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
September 27th 2024

3D bioprinting technology facilitates development of an in vitro biomimetic bladder model

Kate Gessner, MD, PhD Philip Abbosh, MD, PhD
"This exciting and innovative technology has a wide range of possible applications, including tissue engineering, drug development, and precision medicine," write Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
September 25th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

Hannah Clarke
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
© 2024 MJH Life Sciences

All rights reserved.